Jubilant Ingrevia Q1 FY27: Strong Start, Better Mix, and a Rebound in Chemical Intermediates

Jubilant Ingrevia began FY27 with a strong first quarter. Consolidated revenue rose to INR 1,300 crore in Q1 FY27, up 25% year on year and 10% sequentially. Profitability improved faster than sales. EBITDA increased to INR 209 crore, up 36% year on year, taking EBITDA margin to 16%. PAT after exceptional items came in at INR 106 crore, up 41% year on year, with net margin improving to 8%.

Management attributed the quarter’s momentum to a combination of healthy volumes and improved realizations, while also highlighting its ability to pass through higher input costs amid supply chain and pricing disruptions linked to geopolitical developments in the Middle East.

A quarter powered by all three segments

The quarter was notable for the fact that all three operating segments delivered year-on-year growth, but the earnings mix shifted. Specialty Chemicals remained the largest profit contributor, but Chemical Intermediates produced a sharp recovery in EBITDA. Nutrition continued its steady margin expansion, delivering its best EBITDA in three years.

Specialty Chemicals reported revenue of INR 533 crore, up 11% year on year, supported by Fine Chemicals and CDMO. Segment EBITDA was INR 139 crore, up 7% year on year, with EBITDA margin at 26%.

Nutrition and Health Solutions delivered revenue of INR 243 crore, up 36% year on year, with EBITDA of INR 36 crore, up 45% year on year. EBITDA margin improved to 15%.

Chemical Intermediates posted revenue of INR 524 crore, up 38% year on year, but the key surprise was profitability. Segment EBITDA jumped to INR 57 crore versus INR 17 crore in Q1 FY26, lifting EBITDA margin to 11%.

Financial snapshot

Specialty Chemicals: Fine Chemicals and CDMO remain the growth engines

In Specialty Chemicals, management highlighted steady volumes in Pyridine and Picolines, improved pricing, and cost rationalization efforts. The company acknowledged pricing pressure in commoditized pyridine building blocks due to overcapacity in China, but stated that a growing share of downstream derivatives and picolines is helping it manage the pressure.

Fine Chemicals continued to build momentum, with volume growth and improved pricing across pyridine and diketene derivative portfolios. In personal care, the company stated it has over 20 products under development and is seeing rising customer traction across sun care, skin care, and hair care. The industrial chemicals pipeline was also described as expanding, with continued traction among existing customers and new customer additions.

CDMO was positioned as an increasingly central pillar of the Pinnacle strategy. Management highlighted stable momentum in the agro segment, supported by the rollout of dispatches for a large innovator CDMO program. In pharma, management cited strong customer traction, supported by US and Europe roadshows that reportedly expanded the pipeline by more than threefold with innovators and Tier-1 CDMOs.

The company also reiterated that its CDMO and Fine Chemicals funnel has crossed 100 molecules, with INR 3,500 crore plus peak revenue potential, and 25 plus molecules now classified as confirmed. It stated that five new molecules were added during the quarter across pharma, semicon, and personal care.

Nutrition: pricing and mix drive the best EBITDA in three years

Nutrition and Health Solutions extended its growth streak in Q1 FY27. Management attributed performance to strong realizations in niacinamide and choline, stable demand across markets, and a favorable product mix.

In Human Nutrition, niacinamide volumes grew steadily. Pricing improved across food and cosmetics applications, while choline chloride and CBT pricing also strengthened on the back of customer engagement across India, Europe, and the US. In premixes, the company said it is seeing stronger engagement with Tier-1 customers in India following the integration of Remidex.

In Animal Nutrition, Vitamin B3 volumes remained steady while pricing improved materially on both year-on-year and sequential bases. Choline maintained domestic share and continued to see demand from Europe with improved realizations. Premixes also delivered volume growth, aided by favorable mix.

Management shared additional operating commentary in the concall around its human-grade plant built for 5,000 tons annual capacity for niacin and niacinamide cosmetic grade. It stated that current volumes are running at about 50% of that run rate, with a target to reach 70% plus by the end of the year.

Chemical Intermediates: a sharp rebound, but management stays cautious

Chemical Intermediates delivered the largest EBITDA swing in the quarter. The segment’s performance was supported by strong volume growth, improved realizations, and effective input cost pass-through, with elevated raw material costs linked to Middle East disruptions.

Acetic Anhydride volumes remained steady, supported by resilient pharma demand, higher European market share, and stable domestic merchant share. Management highlighted strong double-digit price growth on both a sequential and year-on-year basis.

Ethyl Acetate volumes grew strongly year on year and pricing improved on both a sequential and year-on-year basis, supported by elevated input costs.

Despite the performance, management acknowledged that acetyl spreads can be volatile. During Q&A, the company reiterated confidence in sequential improvement but stated that uncertainty in Q3 and Q4 market conditions is a key reason it is not changing overall guidance.

Revenue mix and geographic scaling

The company provided revenue mix disclosures that show a balanced business profile.

By business, Q1 FY27 revenue split was:

• Specialty Chemicals: 41%
• Chemical Intermediates: 40%
• Nutrition and Health Solutions: 19%

By application, Q1 FY27 revenue split was:

• Pharma: 30%
• Industrial: 26%
• Nutrition: 21%
• Agro: 20%
• Consumer: 3%

By geography, Q1 FY27 revenue split was:

• India: 52%
• Europe: 26%
• North America: 11%
• Rest of World: 11%

Management highlighted that North America and Europe together now account for more than 37% of revenue.

Strategy execution: Pinnacle, MPP commissioning, semicon build-out

Management continues to anchor its narrative around the Pinnacle journey, built on growth pillars across Specialty Chemicals, Nutrition, and Chemical Intermediates, and enabled by customer-first key account management, operational excellence, R&D, digital transformation, and agile supply chain.

Operationally, the company reiterated a FY27 lean savings target of INR 100 crore. It also stated that the Multi-Purpose Plant is on track for commissioning by the end of calendar year 2026, positioning it as an important enabler for CDMO and Fine Chemicals expansion.

A newer theme in the presentation is the electronics and semiconductor vertical. Jubilant Ingrevia stated that it has 10 plus customers across the US, Europe, and Japan and 15 plus products in the pipeline, including catalogue products E-Pyridine and E-Choline, with multiple products under qualification. The company is setting up a semiconductor lab at Greater Noida and planning clean room facilities, while also developing purification technology.

Guidance and what to watch

Management’s forward commentary remained optimistic but measured. It reiterated that for FY27, growth is expected to be led by Specialty Chemicals and Nutrition, alongside a recovery in acetyls. It expects sequential improvement in revenue and EBITDA in the coming quarters.

On guidance, the CFO reiterated the full-year EBITDA range of INR 750 crore to INR 800 crore.

Two items stand out for monitoring through FY27. First, volume visibility on the large agro CDMO program remains uncertain. Management stated the customer has not provided a firm timeline for full visibility, though it expects more clarity for near-term planning within the next month or so. Second, chemical intermediates spreads have improved sharply, but management itself emphasized that the segment can reverse quickly depending on market conditions.

Overall, Q1 FY27 reflects better execution, stronger mix, and improving end-market traction in high-margin areas such as CDMO, fine chemicals and premium nutrition grades. The next few quarters will test whether the momentum can be sustained as the company ramps new capacity and navigates volatility in acetyls and global input costs.